 |
|
Expectations From Clinical Trials
Results of the Early Manifest Glaucoma Trial
Arch Ophthalmol. 2002;120:1371-1372.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
PHYSICIANS REGULARLY look for indications of the best practices so that
they can appropriately advise and treat their patients. Readers of this month's
ARCHIVES will have considerable interest in the first results from the Early
Manifest Glaucoma Trial1 (EMGT), a National
Eye Institute (NEI)–sponsored study to determine whether patients with
newly diagnosed glaucoma can benefit from treatment that reduces their intraocular
pressure (IOP). The EMGT may be the only clinical trial for glaucoma that
will ever include an untreated study arm of patients known to have the disease.
Although some readers may wonder whether it was ethical not to treat a patient
with glaucomatous damage, the study was carefully designed so that untreated
patients who showed the earliest progression of the disease were immediately
offered treatment. Thus, no patients were allowed to lose a significant amount
of visual field while going untreated.
Other investigators may ask why this study was . . . [Full Text of this Article]
RELATED ARTICLE
Reduction of Intraocular Pressure and Glaucoma Progression: Results From the Early Manifest Glaucoma Trial
Anders Heijl, M. Cristina Leske, Bo Bengtsson, Leslie Hyman, Boel Bengtsson, Mohamed Hussein, and for the Early Manifest Glaucoma Trial Group
Arch Ophthalmol. 2002;120(10):1268-1279.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Impact of Intraocular Pressure Reduction on Glaucoma Progression
Lichter
JAMA 2002;288:2607-2608.
FULL TEXT
|
